FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review